1369932-65-9

Upstream product

• 1380316-29-9 ethyl 4-isopropoxy-2-nitrobenzoate 
• 104356-27-6 ethyl 4-hydroxy-2-nitrobenzoate 

Downstream Products

• 1380316-31-3 1-(bromomethyl)-4-isopropoxy-2-nitrobenzene 
• 1380316-32-4 tert-butyl N-(diphenylmethylene)-O-isopropyl-2-nitro-L-tyrosinate 
• 1380316-33-5 O-isopropyl-2-nitro-L-tyrosine hydrochloride 

Relevant academic research and scientific papers

IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE

Disclosed are compounds of formula (I), (II), (III), and (IV), and pharmaceutically acceptable salts thereof. The compounds are inhibitors of ALK2 kinase. Also provided are pharmaceutical compositions comprising a compound of formula (I), (II), (III), or (IV), or pharmaceutically acceptable salt thereof, and methods involving use of the compounds or pharmaceutically acceptable salts thereof and compositions in the treatment and prevention of various diseases and conditions, such as fibrodysplasia ossificans progressiva.

KAT II INHIBITORS

The present invention relates to compounds 3-amino-1-hydroxy-2-oxo-1,2,3,4-tetrahydroquinoline-7-carbonitrile, 3-amino-1-hydxoxy-7-(2-methoxyethoxy)-3,4-dihydro-quinolin-2(1H)-one, and 3-amino-1-hydroxy-7-[(1S)-2-methoxy-1-methylethoxy]-3,4-dihydroquinolin-2(1H)-one, including racemic mixtures and resolved enantiomers thereof, to pharmaceutically acceptable salts thereof, and to the treatment of cognitive deficits associated with schizophrenia and other psychiatric, neurodegenerative and/or neurological disorders in mammals, including humans